Fed Governor Adriana Kugler to resign
HINGHAM, Mass. - Microbot Medical Inc. (NASDAQ:MBOT), known for its LIBERTY Endovascular Robotic System, is slated to be included in the preliminary list of additions to the Russell Microcap Index, as per FTSE Russell’s announcement on May 23, 2025. The company has shown remarkable market performance, with a 190% price return over the past six months, according to InvestingPro data. This inclusion is part of the annual reconstitution of Russell indexes, which will become effective after market close on June 27, 2025, and will reflect in the market from June 30, 2025.
The Russell Microcap Index captures the 4,000 largest US stocks by market capitalization as of April 30, 2025. Companies listed in this index are automatically included in the appropriate growth and value style indexes for one year. FTSE Russell determines index membership based on objective market-capitalization rankings and style attributes.
Russell indexes, which benchmark approximately $10.6 trillion in assets as of June 2024, are utilized by investment managers and institutional investors for creating index funds and as benchmarks for active investment strategies.
Microbot Medical, a pre-commercial stage medical technology company, has developed what it claims to be the world’s first single-use, fully disposable endovascular robotic system. The company aims to eliminate traditional barriers to advanced robotic systems, intending to enhance the quality of care for patients and providers globally. InvestingPro data shows the company maintains a strong financial position with a current ratio of 16.19, indicating robust liquidity, and holds more cash than debt on its balance sheet.
The inclusion in the Russell Microcap Index is subject to final confirmation and could potentially increase the visibility of Microbot Medical within the investment community.
Microbot Medical has issued forward-looking statements regarding its financial and operational prospects, including its inclusion in the final list for the Russell Microcap Index and the commercialization of its LIBERTY Endovascular Robotic System. However, these statements involve risks and uncertainties, including the need for additional capital, market conditions, and regulatory approvals.
Investors are reminded that forward-looking statements are not guarantees of future performance and that actual results may differ materially. According to InvestingPro analysis, analysts do not anticipate profitability this year, with an EPS forecast of -$0.36 for 2025. Additional information on risks facing Microbot Medical can be found in the company’s SEC filings, which are publicly available. InvestingPro subscribers have access to 8 additional key insights about MBOT’s financial health and market position.
This news is based on a press release statement from Microbot Medical Inc.
In other recent news, Microbot Medical has reported successful results from its ACCESS-PVI pivotal trial of the LIBERTY Endovascular Robotic System. The trial, conducted at prominent medical institutions, achieved a 100% success rate in robotic navigation and significantly reduced radiation exposure for operators. No adverse device events were reported, and the trial outcomes were presented at the Society of Interventional Radiology’s annual meeting. Following these results, H.C. Wainwright maintained a Buy rating on Microbot Medical with a $9.00 price target, citing an increased probability of FDA 510(k) clearance for the LIBERTY system. Additionally, Microbot Medical has amended its by-laws to lower the quorum requirement for shareholder meetings, which is now one-third of the votes entitled to be cast on a matter. This change comes as the company prepares for its annual stockholders’ meeting in June 2025. The company also announced the appointment of new senior officers to strengthen its U.S. commercial leadership team ahead of an anticipated FDA decision. Lastly, Microbot Medical filed a Preliminary Proxy Statement with the SEC for its upcoming annual meeting after failing to achieve a quorum for a previously planned special meeting.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.